Mr. George Achilleos reports

NETRAMARK SIGNS TWO CONTRACTS WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS

Netramark Holdings Inc. has signed two contracts with a large publicly listed biopharmaceutical company, pursuant to the previously announced master service agreement on Oct. 31, 2023.

Netramark will employ its proprietary Attractor artificial intelligence technology to analyze clinical trial data provided from two of the biopharmaceutical company's distinct phase II candidate medicines.

The primary objectives of the contracts are as follows:

• Enable the generation of novel insights and hypotheses with regard to each study's patient population;
• Identify drug and placebo response persona characteristics;
• Perform adverse event and risk modelling;
• Output specific hypotheses that inform enrichment and recruitment criteria for coming late-phase studies.

"This marks a significant milestone for Netramark, as it provides further validation of our NetraAI solutions for pharmaceutical companies with late-phase clinical assets. We are confident that these projects will demonstrate Netramark's generative AI offerings and how they can meaningfully impact drug development programs," said Netramark chief executive officer George Achilleos.

Netramark is well positioned to empower pharmaceutical companies and their respective contract research organizations (CROs) with critical scientific insights to accelerate speed, quality and accuracy across their clinical strategy protocol designs that drive improved patient outcomes and operational results.

Netramark is also pleased to announce that it will be attending the 42nd annual JPM Healthcare conference to meet with clients, partners and the banking community.

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of generative artificial intelligence (Gen AI)/machine learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activate traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.